High-flow Nasal Oxygenation During Preoxygenation and Atelectasis

NCT ID: NCT06205212

Last Updated: 2024-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-10

Study Completion Date

2024-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atelectasis after induction of general anesthesia is common even in healthy patients and is clinically problematic, especially in obese patients. We aim to investigate whether preoxygenation with high-flow nasal oxygen during anesthesia induction reduces atelectasis in obese patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia, General Pulmonary Atelectasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

facemask

preoxygenation using a conventional facemask

Group Type ACTIVE_COMPARATOR

facemask

Intervention Type OTHER

preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min

high-flow nasal oxygen

preoxygenation using high-flow nasal cannula oxygen

Group Type EXPERIMENTAL

high-flow nasal oxygen

Intervention Type OTHER

preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

high-flow nasal oxygen

preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min

Intervention Type OTHER

facemask

preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults patients undergoinig surgery under general anesthesia with a BMI of 30 kg/m2 or greater who have given informed consent

Exclusion Criteria

* surgery time less than 2 hours
* Nasotracheal intubation
* Severe cardiac or respiratory disease
* History of difficult airway
* History of a surgery or anatomical anomaly in the head and neck
* History of Inability to breathe through nose
* Gastric reflux disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SMG-SNU Boramae Medical Center

OTHER

Sponsor Role collaborator

Seoul National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

TAE KYONG KIM

Role: PRINCIPAL_INVESTIGATOR

SMG-SNU Boramae Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

SMG - SNU Boramae Medical Center

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

TAE KYONG KIM

Role: CONTACT

82-2-870-2519

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tae Kyong Kim, MD

Role: primary

82-2-2072-2467

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HFNO_PRE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.